Abionic attracts venture funding from leading Swiss firms
Abionic SA, a Swiss MedTech company focused on allergy diagnostics, announced today the closing of a CHF 2 million first financing round led by MedHoldings SA. Abionic is developing a portable biomedical device that has the potential to revolutionize the diagnosis of allergies.
The first financing round of Abionic was led by MedHoldings SA. MedHoldings SA is a Lausanne based Private Equity and Venture Capital investment company, focusing primarily on development and late stage Medtech ventures in Switzerland, Europe and Emerging Markets. Other investors include Polytech Ventures & Cie SCPC, Blue Ocean Ventures, Business Angels Switzerland (BAS) and Fongit Seed Invest. Several private investors also participated in this financing round.
<!--[if gte mso 9]> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="fa
Please login or sign up to comment.
Commenting guidelines